| Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET (NCT01374451) | Novartis Pharmaceuticals | 2011-06-01 |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors (NCT00427349) | Eastern Cooperative Oncology Group | 2008-11-07 |
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization (NCT00434109) | H. Lee Moffitt Cancer Center and Research Institute | 2006-11-01 |
| Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors (NCT00454376) | National Cancer Institute (NCI) | 2006-10-01 |
| Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors (NCT00602082) | Cambridge University Hospitals NHS Foundation Trust | 2005-08-01 |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors (NCT00227617) | University of California, San Francisco | 2005-06-08 |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery (NCT00416767) | Federation Francophone de Cancerologie Digestive | 2004-05-01 |
| Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors (NCT00466856) | Vanderbilt-Ingram Cancer Center | 2003-12-01 |
| Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors (NCT00049023) | O'Dorisio, M S | 2002-01-01 |
| PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors (NCT00017199) | Ohio State University Comprehensive Cancer Center | 2001-04-01 |
| Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors (NCT00027638) | Memorial Sloan Kettering Cancer Center | 2001-03-01 |
| Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders (NCT00830557) | Mayo Clinic | 2000-10-01 |
| Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases (NCT00019786) | National Institutes of Health Clinical Center (CC) | 1999-08-01 |
| Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer (NCT00006368) | Novartis Pharmaceuticals | 1998-01-01 |
| Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer (NCT00002947) | Yale University | 1996-10-01 |